Novartis shares new data on Zolgensma’s safety and efficacy in older and heavier children with Spinal Muscular Atrophy (SMA), showing maintained or improved motor milestones after 52 weeks. Importantly, the study did not identify any new safety concerns with Zolgensma in this patient group.